New Advances in Metabolic Diseases Diagnostics and Treatment: From Basic Research to Clinical Practice
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1129
Special Issue Editor
Interests: mitochondrial metabolism; inherited metabolic disorders; metabolic disorders; biomarkers; metabolomics; drug metabolism; liver disease; steatosis; NAFLD; hepatotoxicity; metabolic dysfunction-associated fatty liver disease (MAFLD)
Special Issue Information
Dear Colleagues,
Our understanding of pathophysiological, metabolism-driven mechanisms is incomplete, especially when multifactorial causes of complex diseases are involved. For Inherited Metabolic Diseases, where a genetic cause underlies the clinical phenotype, the science has evolved markedly during recent decades, and lessons from these rare disorders should be considered in the investigation of common metabolic diseases.
Our goal is to spotlight novel advances in the field of genetic or non-genetic Metabolic Disorders, covering aspects that may range from basic research to clinical diagnosis and monitoring. We hope that reporting new hypotheses and observations may allow researchers to integrate the metabolic processes involving proteins (amino acids), carbohydrates (sugars), or lipids (fatty acids). The regulation of mitochondrial function and bioenergetics, metabolites transport across membranes, intracellular communication, post-translational modifications of proteins, and enzyme activity are crucial in biosynthesis versus degradation pathways. The roles of dietary components or specific small molecules in prevention and/or pathogenesis are also significant. Original research articles and reviews reporting innovations in biomarkers assessments using human samples, human tissues or digital technologies, cell-based assays or models of metabolic disease are encouraged. Comprehensive tools and technologies focusing on metabolomics, proteomics, lipidomics, and multi-omics or multi-modal approaches are of particular interest.
These multiple perspectives will certainly contribute to inspire drug development and better treatment strategies and personalized medicines or ultimately to underline their importance of controlling metabolic diseases fostering a healthier life.
Dr. Margarida F. B. Silva
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolic disease
- inherited metabolic disease
- mitochondrial metabolism
- metabolomics
- multi-omics
- biomarkers
